AbbVie scholarship for students with cystic fibrosis
Editor
April 8, 2017
Thanks to 25-years of medical advancement, the goal of pursuing higher education for many students with cystic fibrosis, an inherited chronic disease that affects the lungs and digestive system, is more achievable than ever before. AbbVie announced the opening of the application period for the AbbVie CF Scholarship program, marking 25 years of honoring students with cystic fibrosis (CF) as they pursue their educational dreams. In honor of the scholarship’s 25th anniversary, AbbVie is also introducing a new award category – the Blogger’s Choice Award. Since its inception in 1993, the program has awarded more than $2.8 million in scholarships to deserving students across the country.
AbbVie will select 40 exceptional students to receive $3,000 for use during the 2017-2018 academic year based on their creativity, academic excellence, community involvement and the ability to serve as a positive role model for the CF community. These 40 recipients will also have the opportunity to compete for public votes to qualify for the title of Thriving Undergraduate or Thriving Graduate Student, and will receive a total scholarship of $25,000 (the original $3,000 scholarship plus an additional $22,000).
New this year, cystic fibrosis bloggers selected by AbbVie will evaluate the creative submissions of the 40 AbbVie CF Scholars to determine which scholar (who is not already receiving a Thriving Student scholarship) will receive the Blogger’s Choice Award. One student will be selected to receive a total of $25,000 in scholarship funding (the original $3,000 scholarship plus an additional $22,000) for use toward education-related expenses.
Applications will be accepted from now until May 24, 2017 and are available online at: www.AbbVieCFScholarship.com. For more information about the application criteria, contest rules and upcoming deadlines surrounding the application process, and to view creative submissions of past winners, visit www.AbbVieCFScholarship.com.
(Blog post on behalf of AbbVie)
